Recent Finacing
Recent Raise
Sermonix Pharmaceuticals develops female-specific oncology therapies, commercializing licensed oral lasofoxifene (SERM) for ESR1‑mutant ER+ metastatic breast cancer and conducting Phase 2 trials versus fulvestrant.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
